Nat Commun:GPX4依赖的癌细胞状态是透明细胞表型的基础并与细胞铁死亡有关

2019-04-22 AlexYang MedSci原创

透明细胞肿瘤(CCCs)是一种高度恶性化的组织,通常起源于肾脏和卵巢。CCCs可以通过异常的脂糖原积累来区分,并且对很多抗癌疗法具有耐受性。最近, 有研究人员鉴定了固有的细胞铁死亡脆弱性与CCCs中独特的细胞代谢状态有关。该脆弱性超越了家系和遗传背景,并且可以通过利用细胞分子来抑制谷胱甘肽过氧化物酶(GPX4)来进行研究。研究人员利用CRISPR筛选和脂质体分析,研究人员鉴定了缺氧诱导因子(HIF

透明细胞肿瘤(CCCs)是一种高度恶性化的组织,通常起源于肾脏和卵巢。CCCs可以通过异常的脂糖原积累来区分,并且对很多抗癌疗法具有耐受性。

最近, 有研究人员鉴定了固有的细胞铁死亡脆弱性与CCCs中独特的细胞代谢状态有关。该脆弱性超越了家系和遗传背景,并且可以通过利用细胞分子来抑制谷胱甘肽过氧化物酶(GPX4)来进行研究。研究人员利用CRISPR筛选和脂质体分析,研究人员鉴定了缺氧诱导因子(HIF)途径是该脆弱性的驱使因子。在肾脏CCCs中,HIF-2α通过激活缺氧诱导的、脂质小滴相关蛋白(HILPDA)来选择性的富集在多聚不饱和脂肪酸中(脂质过氧化反应的限速底物)。

最后,研究人员指出,他们的研究表明了以GPX4为靶标可以作为CCCs的一种治疗选择,并且强调了在不易治愈的癌症中,形态和代谢特性显现出了细胞状态可以作为治疗方法选择的基础。

原始出处:

Yilong Zou, Michael J. Palte, Amy A. Deik et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 08 April 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883686, encodeId=0c3418836860e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 02 21:34:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087541, encodeId=65c7208e541cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 31 04:34:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252593, encodeId=5c67125259379, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423887, encodeId=81eb142388e63, content=<a href='/topic/show?id=b7d1822e38' target=_blank style='color:#2F92EE;'>#GPx4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8227, encryptionId=b7d1822e38, topicName=GPx4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25333863783, createdName=huangshifeng, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535220, encodeId=d1b2153522020, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-07-02 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883686, encodeId=0c3418836860e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 02 21:34:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087541, encodeId=65c7208e541cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 31 04:34:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252593, encodeId=5c67125259379, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423887, encodeId=81eb142388e63, content=<a href='/topic/show?id=b7d1822e38' target=_blank style='color:#2F92EE;'>#GPx4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8227, encryptionId=b7d1822e38, topicName=GPx4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25333863783, createdName=huangshifeng, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535220, encodeId=d1b2153522020, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-07-31 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883686, encodeId=0c3418836860e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 02 21:34:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087541, encodeId=65c7208e541cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 31 04:34:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252593, encodeId=5c67125259379, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423887, encodeId=81eb142388e63, content=<a href='/topic/show?id=b7d1822e38' target=_blank style='color:#2F92EE;'>#GPx4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8227, encryptionId=b7d1822e38, topicName=GPx4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25333863783, createdName=huangshifeng, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535220, encodeId=d1b2153522020, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-04-24 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883686, encodeId=0c3418836860e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 02 21:34:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087541, encodeId=65c7208e541cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 31 04:34:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252593, encodeId=5c67125259379, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423887, encodeId=81eb142388e63, content=<a href='/topic/show?id=b7d1822e38' target=_blank style='color:#2F92EE;'>#GPx4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8227, encryptionId=b7d1822e38, topicName=GPx4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25333863783, createdName=huangshifeng, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535220, encodeId=d1b2153522020, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-04-24 huangshifeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883686, encodeId=0c3418836860e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 02 21:34:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087541, encodeId=65c7208e541cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 31 04:34:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252593, encodeId=5c67125259379, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423887, encodeId=81eb142388e63, content=<a href='/topic/show?id=b7d1822e38' target=_blank style='color:#2F92EE;'>#GPx4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8227, encryptionId=b7d1822e38, topicName=GPx4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25333863783, createdName=huangshifeng, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535220, encodeId=d1b2153522020, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Apr 24 04:34:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-04-24 tastas

相关资讯

2019 ESMO临床实践指南:肾细胞癌的诊断,治疗和随访

2019年2月,欧洲肿瘤内科学会(ESMO)发布了肾细胞癌的诊断,治疗和随访指南,指南主要内容涉及肾细胞癌的诊断以及病理/分子诊断,分期和风险评估,局部疾病的管理,转移性疾病的管理,个体化医疗以及随访和监测。

2019 EAU指南:肾细胞癌(更新版)

2019年2月,欧洲泌尿外科学会(EAU)更新发布了肾细胞癌指南,指南主要内容涉及肾细胞癌的管理,包括诊断分期,分类和预后因素,其他肾脏肿瘤,局部肾肿瘤的治疗,转移性肾肿瘤的系统治疗,监测随访。

Brit J Cancer:肾细胞癌中apelin和apelin受体表达研究

APLNR(apelin受体)是癌症免疫治疗的一个潜在的基因,APLNR的缺失能够导致免疫治疗的失败。最近,有研究人员调查了肾细胞肿瘤(RCC)患者中APLN(apelin)和APLNR的表达,并调查了与临床病理参数和生存的相关性。研究包括了3个详细鉴定过的RCC患者群体:研究群体1(透明细胞RCC;APLN/APLNR mRNA表达;n=166);TCGA验证群体(透明细胞RCC;APLN/AP

Cell Death Dis:肾细胞癌中LXRα能够促进细胞转移

尽管肾细胞肿瘤(RCC)中关于生物标记和靶向治疗的研究在过去几十年取得了很大的进展,但是生物标记和靶向治疗药物在RCC临床中的应用却非常受限制,原因就是它们的自身缺陷或者产生的副作用。肝X受体(LXRs)和NLRP3发炎体在最近这些年时研究的焦点。最近,有研究人员整合了生物信息分析、分子生物学试验和生物功能试验来研究LXRα和NLRP3发炎体在RCC中的作用。研究发现,LXRα表达的提高与RCC不

Cell Death & Disease:肾细胞癌中RBCK1能够通过泛素化途径促进p53降解

肾细胞癌(RCC)大约占据了成年人肿瘤的3%,并且RCC的发生率在世界范围内持续增长。尽管RCC可以在早期阶段通过外科手术来进行治疗,而在晚期患者中5年的生存率却急剧的减少。大多数接受细胞毒性或者靶向药物治疗的RCC患者在治疗期间会在某个时间点产生抗性。因此,鉴定新的RCC治疗靶标是非常必要的。最近,有研究人员发现RANBP2型和包含锌指结构 C3HC4型蛋白 (RBCK1)在人类RCC患者样本中

Sci Rep:透明细胞肾细胞癌肿瘤样本中,评估的肿瘤纯度对基于药物重定位的基因表达影响研究

最近,有研究人员为了发现之前用于治疗其他疾病药物中,能够治疗透明细胞肾细胞癌(ccRCC)的药物,他们之前搜寻了预期能够将来自癌症基因组计划中的500+ccRCC样本的基因表达水平回归到健康肾组织样本基因表达水平的药物。他们研究中的混样池RNA-seq数据的内在限制为肿瘤样本包含了各种各样的癌细胞和非癌细胞,影响了差异基因表达分析。在新的研究中,研究人员通过研究与肿瘤纯度的相关性,调查了是否候选药